| Official Full Name |
Recombinant Human Interleukin-36 beta, 157a.a. (rHuIL-36beta,157a.a.) |
| Squence |
 |
| Amino Acid Sequence |
MNPQREAAPK SYAIRDSRQM VWVLSGNSLI AAPLSRSIKP VTLHLIACRD TEFSDKEKGN MVYLGIKGKD LCLFCAEIQG KPTLQLKEKN IMDLYVEKKA QKPFLFFHNK EGSTSVFQSV SYPGWFIATS TTSGQPIFLT KERGITNNTN FYLDSVE |
| 别名 |
FIL1 eta, IL-1 eta, IL-1F8, IL-1H2 |
| Accession Number |
Q9NZH7-2 |
| GeneID |
27177 |
| Summary |
Interleukin-36 (IL-36) is a pro-inflammatory cytokine which plays an important role in the pathophysiology of several diseases. IL-36alpha, IL-36β, and IL-36gamma (formerly IL-1F6, IL-1F8, and IL-1F9) are IL-1 family members that signal through the IL-1 receptor family members IL-1Rrp2 (IL-1RL2) and IL-1RAcP. IL-36 beta is reported to be expressed at higher levels in psoriatic plaques than in symptomless psoriatic skin or healthy control skin. Furthermore, it can stimulate production of interleukin-6 and interleukin-8 in synovial fibroblasts, articular chondrocytes and mature adipocytes. Two alternatively spliced transcript variants encode distinct (164 or 157 residues) protein isoforms that differ in their C-terminal 70 amino acid residues have been reported and IL-36β isoform 2 is synthesized as a 157 a.a. protein. Specifically, human IL-36β shares low sequence identity with IL-1β, IL-36RA, IL-36alpha and IL-36gamma. |
| Source |
Escherichia coli. |
| 分子量 |
Approximately 17.7kDa, a single non-glycosylated polypeptide chain containing 157 amino acids. |
| Biological Activity |
Fully biologically active when compared to standard. The specific activity is determined by its binding ability in a functional ELISA. Immobilized rHuIL-36β at 1 ug/mL can bind recombinant human IL-1 Rrp2 Fc Chimera with a range of 0.15-5 ug/mL. |
| Appearance |
Sterile filtered white lyophilized (freeze-dried) powder. |
| Formulation |
Lyophilized from a 0.2 um filtered concentrated solution in PBS, pH 7.4. |
| Endotoxin |
Less than 1 EU/ug of rHuIL-36β, 157a.a. as determined by LAL method. |
| Reconstitution |
We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1 % BSA to a concentration of 0.1-1.0 mg/mL. Stock solutions should be apportioned into working aliquots and stored at ≤ -20 °C. Further dilutions should be made in appropriate buffered solutions. |
| Stability and Storage |
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.- 12 months from date of receipt, -20 to -70 °C as supplied.- 1 month, 2 to 8 °C under sterile conditions after reconstitution.- 3 months, -20 to -70 °C under sterile conditions after reconstitution. |
| References |
|
| SDS-PAGE |
 |
| Safety Data Sheet (SDS) Download |
Click to download |
| Technical Data Sheet (TDS) Download |
Click to download |
